Skip to content
lifestyle.brickvest.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Structure Therapeutics Inc.
Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions
May 24, 2026
Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel
May 21, 2026
Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
May 17, 2026
Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron
May 17, 2026